Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Subscribe To Our Newsletter & Stay Updated
